ABT 436

Drug Profile

ABT 436

Alternative Names: ABT-436

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; National Institute on Alcohol Abuse and Alcoholism
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Vasopressin 1b receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Anxiety disorders; Major depressive disorder

Most Recent Events

  • 01 Mar 2015 AbbVie completes a phase II trial in Alcoholism in USA (NCT01613014)
  • 04 Oct 2013 AbbVie terminates phase II trial in Major depressive disorder in the US (NCT01741142)
  • 03 Jun 2013 AbbVie suspends a phase II trial in Major depressive disorder in USA (NCT01741142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top